Cargando…
Lipooxygenase inhibition in osteoarthritis: a potential symptomatic and disease modifying effect?
5-Loxin(® )is a compound extracted from an ancient herb that might be considered as a potent lipooxygenase inhibitor. The results observed in a preliminary trial suggest a highly intriguing clinically relevant symptomatic effect contrasting with a poor bioavailability of this compound. Moreover, in...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592778/ https://www.ncbi.nlm.nih.gov/pubmed/18828886 http://dx.doi.org/10.1186/ar2490 |
_version_ | 1782161578872799232 |
---|---|
author | Dougados, Maxime |
author_facet | Dougados, Maxime |
author_sort | Dougados, Maxime |
collection | PubMed |
description | 5-Loxin(® )is a compound extracted from an ancient herb that might be considered as a potent lipooxygenase inhibitor. The results observed in a preliminary trial suggest a highly intriguing clinically relevant symptomatic effect contrasting with a poor bioavailability of this compound. Moreover, in this trial, a statistically significant decrease in matrix metalloproteinase enzyme serum level suggests that, in addition to the observed symptomatic effect, such a compound might have a disease modifying effect in osteoarthritis. Further studies are required both to confirm the symptomatic efficacy and acceptable safety profile and to evaluate the potential chondromodulating effect of this compound. |
format | Text |
id | pubmed-2592778 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-25927782008-12-03 Lipooxygenase inhibition in osteoarthritis: a potential symptomatic and disease modifying effect? Dougados, Maxime Arthritis Res Ther Editorial 5-Loxin(® )is a compound extracted from an ancient herb that might be considered as a potent lipooxygenase inhibitor. The results observed in a preliminary trial suggest a highly intriguing clinically relevant symptomatic effect contrasting with a poor bioavailability of this compound. Moreover, in this trial, a statistically significant decrease in matrix metalloproteinase enzyme serum level suggests that, in addition to the observed symptomatic effect, such a compound might have a disease modifying effect in osteoarthritis. Further studies are required both to confirm the symptomatic efficacy and acceptable safety profile and to evaluate the potential chondromodulating effect of this compound. BioMed Central 2008 2008-09-19 /pmc/articles/PMC2592778/ /pubmed/18828886 http://dx.doi.org/10.1186/ar2490 Text en Copyright © 2008 BioMed Central Ltd |
spellingShingle | Editorial Dougados, Maxime Lipooxygenase inhibition in osteoarthritis: a potential symptomatic and disease modifying effect? |
title | Lipooxygenase inhibition in osteoarthritis: a potential symptomatic and disease modifying effect? |
title_full | Lipooxygenase inhibition in osteoarthritis: a potential symptomatic and disease modifying effect? |
title_fullStr | Lipooxygenase inhibition in osteoarthritis: a potential symptomatic and disease modifying effect? |
title_full_unstemmed | Lipooxygenase inhibition in osteoarthritis: a potential symptomatic and disease modifying effect? |
title_short | Lipooxygenase inhibition in osteoarthritis: a potential symptomatic and disease modifying effect? |
title_sort | lipooxygenase inhibition in osteoarthritis: a potential symptomatic and disease modifying effect? |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592778/ https://www.ncbi.nlm.nih.gov/pubmed/18828886 http://dx.doi.org/10.1186/ar2490 |
work_keys_str_mv | AT dougadosmaxime lipooxygenaseinhibitioninosteoarthritisapotentialsymptomaticanddiseasemodifyingeffect |